Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
2. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide
3. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
4. Re-021
1. 254740-64-2
2. Sparsentan (re-021)
3. Re-021
4. Sparsentan [usan]
5. Ps433540
6. Ps-433540
7. 9242ro5urm
8. Chembl539423
9. 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
10. 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-n-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
11. Retrophin
12. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
13. [1,1'-biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
14. Unii-9242ro5urm
15. Dara
16. Compound 7 [pmid 15634011]
17. Dara-a
18. Ps 33540
19. Sparsentan [inn]
20. Sparsentan (usan/inn)
21. Sparsentan(ps433540)
22. Sparsentan [who-dd]
23. Schembl535109
24. Gtpl8448
25. Amy38147
26. Bcp23969
27. Ex-a3048
28. Bdbm50175523
29. S6665
30. Cs-7947
31. Db12548
32. Sb16876
33. Dara-a (dual Acting Receptor Antagonist Of Angiotension And Endothelin Receptors)
34. Ps-433540;re-021;dara
35. Ac-35179
36. Hy-17621
37. Sparsentan (ps-433540,re-021,dara)
38. D11776
39. F77045
40. A858308
41. L023324
42. Q27088845
43. 4''''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide
44. 4''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide
45. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyi)-n-(4,5- Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
46. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide
47. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
Molecular Weight | 592.8 g/mol |
---|---|
Molecular Formula | C32H40N4O5S |
XLogP3 | 5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 12 |
Exact Mass | 592.27194156 g/mol |
Monoisotopic Mass | 592.27194156 g/mol |
Topological Polar Surface Area | 123 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 1060 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of focal segmental glomerulosclerosis
Treatment of primary IgA nephropathy
Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...
About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...
About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...
About the Company : For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacture...
About the Company : Hebi Xinhe Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Zhennuo Pharmaceutical Group Co., Ltd., with a registered capital of CNY 100 million. Located in Jijiashan Industrial...
Details:
Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Not Applicable
Deal Type : Not Applicable
CSL Vifor, Travere Announce Swiss Approval of FILSPARI® For IgA Nephropathy
Details : Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 17, 2024
Details:
Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Ligand Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Ligand Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Travere Receives Full FDA Approval for FILSPARI® in IgA Nephropathy
Details : Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2024
Details:
RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: RE-021
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renalys Pharma Doses First Patient in Phase III Trial of Sparsentan for IgA Nephropathy
Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.
Brand Name : RE-021
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 18, 2024
Details:
The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: RE-021
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Catalys Pacific
Deal Size: $38.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 17, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Catalys Pacific
Deal Size : $38.8 million
Deal Type : Series A Financing
Renalys Pharma Closes ¥60Bn Financing to Advance Kidney Disease Treatments in Asia
Details : The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.
Brand Name : RE-021
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 17, 2024
Details:
Filspari (sparsentan) is an oral medication targeting critical pathways in IgAN progression, approved for treating IgA nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Not Applicable
Deal Type : Not Applicable
CSL Vifor and Travere Announce EU Approval of FILSPARI® for IgA Nephropathy
Details : Filspari (sparsentan) is an oral medication targeting critical pathways in IgAN progression, approved for treating IgA nephropathy.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication targeting critical pathways in IgAN, approved for the treatment of IgA nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renalys Submits IND Application for Sparsentan Phase III Trial in Japan
Details : Filspari (sparsentan) is a once-daily oral medication targeting critical pathways in IgAN, approved for the treatment of IgA nephropathy.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2024
Details:
Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Travere Submits Supplemental Application for Full Approval of FILSPARI®
Details : Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2024
Details:
Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Not Applicable
Deal Type : Not Applicable
Travere and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion
Details : Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2024
Details:
Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Renalys Pharma
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 25, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Renalys Pharma
Deal Size : $120.0 million
Deal Type : Licensing Agreement
Travere Announces Agreement with Renalys for Sparsentan in Japan and Southeast Asia
Details : Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 25, 2024
Details:
Filspari (sparsentan) is an oral medication targeting key pathways in IgAN disease progression, approved for treating IgA nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Brand Name: Filspari
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Lead Product(s) : Sparsentan
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renalys Pharma Launches Innovative Medicines in Japan and Asia
Details : Filspari (sparsentan) is an oral medication targeting key pathways in IgAN disease progression, approved for treating IgA nephropathy.
Brand Name : Filspari
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 25, 2024
Regulatory Info : RX
Registration Country : USA
Brand Name : FILSPARI
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Packaging :
Approval Date : 2023-02-17
Application Number : 216403
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : FILSPARI
Dosage Form : TABLET;ORAL
Dosage Strength : 400MG
Packaging :
Approval Date : 2023-02-17
Application Number : 216403
Regulatory Info : RX
Registration Country : USA
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?